Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis;...
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks.
Target Price
The average target price of GNFT.PA is 13 and suggests 48% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incre
Buy
Sell